Clinical trials
Autosomal Dominant Polycystic Kidney clinical trials
Below are recruiting autosomal dominant polycystic kidney clinical trials, each written for real people, not researchers. We’re tracking 29 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05478083RecruitingPhase 2
Leuprolide treatment for severe polycystic liver growth
This Phase 2 study tests whether a monthly hormone medicine (leuprolide, a GnRH agonist given as an injection) can slow down ongoing, fast-growing polycystic livers. It is aimed at pre-menopausal women with very large livers that are still getting bigger on past and current scans.
Nijmegen, GelderlandAges 18–45 - NCT06065852Recruiting
National registry for rare kidney diseases
This study creates a registry to collect health information from people with rare kidney diseases. It aims to improve understanding and future treatments by tracking patient experiences.
Bristol, South WestAges Any age - NCT07792408RecruitingPhase 1
Study of VX-407 and oral contraceptive interaction
This study tests how a new drug, VX-407, affects the levels of a combined oral contraceptive in your body. Participants must be healthy adults aged 18 to 65 with a certain body weight and BMI.
MontrealAges 18–50 - NCT07788014RecruitingPhase 1
Testing a new medicine for healthy adults
This study tests a new investigational drug called GV-100 to see how safe it is and how the body handles it. It is for healthy adults and will be given in different doses to find the best one.
Adelaide, South AustraliaAges 18–65 - NCT07745920Recruiting
An online program for depression in people with adpkd
This study tests an internet-based program to help manage depression symptoms in people with ADPKD. The program may be a convenient way to get support for your mood without traveling to a clinic.
Rochester, MinnesotaAges 18–70 - NCT06618638Recruiting
Shared Decision Tool for ADPKD Treatment
This study helps people with ADPKD and moderate kidney damage decide together with their doctor whether to start a treatment called tolvaptan. It tests a shared decision-making tool to see if it helps patients understand their options better.
Anyang-si, Gyeonggi-doAges 18–80 - NCT07535385Recruiting
Kidney Artery Blocking Treatment for Polycystic Kidney Disease
This study follows patients with a genetic kidney disease (autosomal dominant polycystic kidney disease) who are on dialysis and receive a procedure to block blood flow to their enlarged kidneys. Researchers will track how well the procedure works and how it affects patients over time using imaging scans.
Pavia, LombardyAges 18–75 - NCT06759142Recruiting
Study of people with ADPKD
This study looks at people with autosomal dominant polycystic kidney disease to learn more about the condition. It is an observational study, meaning no new treatments are tested—just gathering information from your medical history and tests.
BolognaAges 18 years+ - NCT07454174Recruiting
Study of a dietary program for polycystic kidney disease
This study tests a special medical food (Ren-Nu) to see if it helps with metabolism and kidney health in people with ADPKD. You would follow a dietary program and attend online classes.
Cleveland, OhioAges 18 years+ - NCT07282821RecruitingPhase 2
Bempedoic acid for polycystic kidney disease
This trial tests if the cholesterol-lowering drug bempedoic acid can slow kidney function loss in people with autosomal dominant polycystic kidney disease (ADPKD). It may offer a new option to protect your kidneys.
Baltimore, MarylandAges 18–60 - NCT07280585RecruitingPhase 3
Testing a diabetes drug to slow kidney disease progression
This study tests whether a common diabetes medication (SGLT2 inhibitor) can help people with autosomal dominant polycystic kidney disease (ADPKD) maintain kidney function longer. If you have fast-growing kidney cysts and are between 18 and 60 years old, this trial may be an option.
FeldkirchAges 18–60 - NCT07260071Recruiting
High blood pressure in kids at risk for inherited kidney disease
This study looks for early signs of high blood pressure in children and teens (12–17) who have a parent with ADPKD, a kidney condition. It uses non-invasive tests like blood pressure monitoring and MRI to track kidney health.
LondonAges 12–17 - NCT07228364RecruitingPhase 1
Testing safety of AZD1613 for polycystic kidney disease
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
Birmingham, AlabamaAges 18–65 - NCT06582875RecruitingPhase 2
GLP-1 drug for polycystic kidney disease and weight
This study tests a GLP-1 receptor agonist (a type of medicine that helps with weight and metabolism) in people with polycystic kidney disease who are overweight. It aims to see if this drug can help slow kidney disease progression.
Aurora, ColoradoAges 18–65 - NCT06902558RecruitingPhase 2
Study of ABBV-CLS-628 for adults with polycystic kidney disease
This trial tests a new drug, ABBV-CLS-628, for people with autosomal dominant polycystic kidney disease (ADPKD). The goal is to see if it slows kidney function decline and is safe to use.
Birmingham, AlabamaAges 18–55 - NCT06800651RecruitingPhase 2
A new drug for fast-growing polycystic kidney disease
This trial tests a drug (JMKX003142) for people with autosomal dominant polycystic kidney disease that is getting worse quickly. It may help slow down kidney damage.
Beijing, Beijing MunicipalityAges 18–55 - NCT06714006RecruitingPhase 1
Testing safety of PYC-003 for ADPKD
This study is testing a new investigational medicine called PYC-003 for people with autosomal dominant polycystic kidney disease (ADPKD). It is one of the first studies in humans, so the main goal is to see if the medicine is safe and tolerable. The study is for people with a specific genetic cause (PKD1 mutation) and with certain kidney imaging types.
Southport, Gold CoastAges 18–65 - NCT06291116RecruitingPhase 2
Safety of rotigotine patch for ADPKD patients
This study tests a skin patch called rotigotine to see if it is safe for people with ADPKD. It may help with blood pressure control, but you cannot have advanced kidney failure or certain other health issues.
AmiensAges 18–60 - NCT05996731Recruiting
Using RNA tests to help diagnose rare genetic diseases
This study uses RNA sequencing to find genetic causes of rare diseases that standard DNA tests might miss. It may help people who have symptoms of a rare disease but no clear genetic diagnosis yet.
Ranica, BGAges Any age - NCT05870007Enrolling by invitationPhase 2
Atorvastatin and alkalizing treatment for autosomal dominant PKD
This Phase 2 study tests whether atorvastatin plus an “alkalizing” treatment (sodium bicarbonate) can slow or improve disease effects in people with autosomal dominant polycystic kidney disease (ADPKD). It specifically targets metabolic acidosis (when the body becomes “too acidic”), which may worsen kidney health.
New Taipei CityAges 18 years+ - NCT04939935RecruitingPhase 3
Metformin to slow kidney decline in adults with polycystic kidneys
This Phase 3 study tests whether taking metformin can slow the decline of kidney function in adults with autosomal dominant polycystic kidney disease (ADPKD). You may be eligible if you have ADPKD and signs that your kidneys are starting to decline faster than expected.
Gosford, New South WalesAges 18–70 - NCT04630613Recruiting
Studying NOX4 markers in young adults with ADPKD
This study measures a kidney-related marker (NOX4) and other blood/urine signals in people with early-stage ADPKD to better understand disease activity. It may help researchers identify who is likely to progress and why, though it may not be a treatment study.
Rochester, MinnesotaAges 15–40 - NCT04344769Recruiting
Studying how a kidney-protecting pathway works in ADPKD
This study looks at how the body’s “Nrf2 response” works in people with autosomal dominant polycystic kidney disease (ADPKD). It may help researchers better understand disease biology and future treatments by comparing kidney-related signals in ADPKD patients and healthy volunteers.
Rochester, MinnesotaAges 18–30 - NCT04338048Recruiting
Study for autosomal dominant polycystic kidney disease
This study enrolls people who have been diagnosed with autosomal dominant polycystic kidney disease (ADPKD), a genetic kidney condition that can cause kidney cysts. It aims to learn about this specific form of the disease so better care is possible for the right patients.
Washington D.C., District of ColumbiaAges Up to 18 years
Hear when a new Autosomal Dominant Polycystic Kidney trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for autosomal dominant polycystic kidney?
- Yes. Clin2 currently lists 29 recruiting autosomal dominant polycystic kidney studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a autosomal dominant polycystic kidney trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a autosomal dominant polycystic kidney trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.